Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. - Wikidata - wikimedia - TriplyDB

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

http://www.wikidata.org/entity/Q36431537

about

Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.Pharmacokinetically guided administration of chemotherapeutic agents.Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours Oral topotecan: bioavailablity and effect of food co-administration Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Recent Advances in Upconversion Nanoparticles-Based Multifunctional Nanocomposites for Combined Cancer Therapy.A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.

P2860

Q28361246-577FC98C-040E-4189-8D73-0A59469FF851 Q33344326-1C8657FA-7623-4437-ACA5-A8044BFADDA6 Q33344965-B24FDCF9-DA34-4F1E-BF17-023F2D90F3A6 Q33365080-5584A0D2-007A-4253-9AE9-69540A1332CC Q33366785-11C5438F-A3AE-4B28-8582-622E4D70FE30 Q33375139-755652FB-5400-4EC6-9B1D-5AF844F2A491 Q33378927-EFDA0240-7071-49CD-8014-B9118DD24C7D Q34099816-C1FDDF08-594F-4317-8762-CDBF05F5939F Q35688338-CBA6CD55-CBD0-4AAA-9A6D-109EF5460B72 Q36013320-F87FD920-B0BB-46A5-83B0-4D15D1FD7CF7 Q36614847-DF11A491-A97D-42F6-B7C2-6DB1FF54FA36 Q36620382-2BA12D20-C2E7-4FE3-825C-0C84ED354B5F Q36648316-F7F840E3-B1E0-4EA8-8697-5B669E4842FB Q38617240-9127454C-8335-4839-AD85-026EFDC9F084 Q44937094-38C67686-0501-46B9-9DA2-92331BEF20F9

P2860

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

http://www.wikidata.org/entity/Q36431537

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

1997年學術文章

@zh

1997年學術文章

@zh-hant

name

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@ast

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@en

type

label

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@ast

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@en

prefLabel

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@ast

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@en

P1433

Q36431537-EB506808-EFA7-46D1-ADB0-4937A643A062

P1476

Q36431537-EF478085-1CE5-45A6-8B9F-D5B3ACCAFF15

P2093

Q36431537-227ECACD-59A3-4EEA-8382-684FE3336829

Q36431537-55486C52-CE41-4FFD-8ED4-23ADD24322ED

Q36431537-5EA40F89-0DF8-4DAE-9087-9294D86C4024

Q36431537-772886EE-91F3-45A5-96A9-FD40CDE7391F

Q36431537-83833240-1811-4891-A235-F71704E96B54

Q36431537-93E18BEB-0A7D-42E2-82BF-9BF88ECC6D6B

Q36431537-FDAED84A-3806-4324-AAEB-9396C2327328

P2860

Q36431537-062B5A9B-411C-47FC-A2BD-62A23B8DBFE3

Q36431537-1C0C706E-CD67-46B0-B221-86E48B330393

Q36431537-1E173DC6-B4C7-4AB3-B917-1396ADD4F498

Q36431537-2D2F761B-EF96-452C-885F-F4C6B36400CC

Q36431537-45C67648-75BB-4A7C-A405-CBDDE0C4DB85

Q36431537-4D0A08F7-0B6F-42B3-8F1B-F44BDEFB0AAD

Q36431537-693E4A75-6FBF-4E4D-9315-8751057E3373

Q36431537-6A9CDD8D-BBB6-4B09-9355-68085F83ABB2

Q36431537-74987B3D-206A-48AF-BE31-4C3B75F04B34

Q36431537-7FCC63B2-9D0E-4489-9C83-24FC77BECE21

P2888

Q36431537-569C062C-D5E7-467F-9325-31C182822D39

P304

Q36431537-68382719-2E26-4D09-8668-61A84263FD5B

P31

Q36431537-82902194-7DA4-4A41-AF13-79843686D4A4

P356

Q36431537-6153BE7C-19AF-4804-BB55-976E8D4AFB60

P407

Q36431537-75E992DA-3513-46EB-9C8F-362F81F8E311

P433

Q36431537-68688ADF-2A61-4368-BD6F-A0BF142F553A

P478

Q36431537-E8F4F843-6F6B-4EF5-8C69-D4933F717835

P577

Q36431537-298B3A26-97B6-4C4D-A628-7B0AE069A1DF

P5875

Q36431537-91535AA7-3291-4CCA-8781-BCFA80F63A24

P698

Q36431537-22105180-2FB7-412A-9E69-68F2B627241B

P932

Q36431537-E3C25B01-40AD-42E9-A9B6-CEAC548CF2D1

P356

P1433

British Journal of Cancer

P1476

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

@en

P2093

Beijnen JH

http://www.w3.org/2001/XMLSchema#string

Dubbelman AC

http://www.w3.org/2001/XMLSchema#string

Groot Y

http://www.w3.org/2001/XMLSchema#string

Herben VM

http://www.w3.org/2001/XMLSchema#string

Mandjes IA

http://www.w3.org/2001/XMLSchema#string

ten Bokkel Huinink WW

http://www.w3.org/2001/XMLSchema#string

van Gortel-van Zomeren DM

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.

Topoisomerase-targeting antitumor drugs.

Kinetics of pharmacologic response.

Concepts of synergism and antagonism.

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

DNA topoisomerase I and II as targets for rational design of new anticancer drugs.

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.

Clinical pharmacokinetics of topotecan.

P2888

P304

1500-1508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1997.585

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

1997-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13829131

http://www.w3.org/2001/XMLSchema#string

P698

9400949

http://www.w3.org/2001/XMLSchema#string

P932

2228184

http://www.w3.org/2001/XMLSchema#string